Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HJ Science (华健未来) Pre-IPO: Thoughts on Valuation

HJ Science (华健未来) IPO: Analysis of Deal Terms

HJ Science IPO: Late Move in Crowded Market Dampens Future Growth Prospect

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

<ul>
<li>HJ Science, a China-based clinical-stage biotech company, has passed the hearing for a Hong Kong Chapter 18A listing. CITIC Securities is the sole sponsor.</li>
<li>In this note, we look at the company's core products HJ787, HJ178, and HJ891, and key product HJ197.</li>
<li>We also look at the company's business development, pre-IPO investors, and management team.</li>
</ul>


HJ Science, a China-based clinical-stage biotech company, has passed the hearing for a Hong Kong Chapter 18A listing. CITIC Securities is the sole sponsor.
In this note, we look at the company's core products HJ787, HJ178, and HJ891, and key product HJ197.
We also look at the company's business development, pre-IPO investors, and management team.


HJ Science (华健未来) Pre-IPO: Clinical Evidence Needed for Pipeline Breadth